Ostrowski, M., Jo, Y., Gebrael, G., Ozay, Z. I., Nandakumar, V., Lin, E., Sayegh, N., Srivastava, A., Thomas, V. M., Li, H., Maughan, B. L., Agarwal, N., Swami, U. (2026). Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.101